Поступление лекарства на фармакологический рынок ожидается в 2018 году.
Японская фармацевтическая компания Shionogi & Co. представила первое в мире лекарство для лечения гриппа, способное справиться с болезнью за один день, пишет газета Nikkei. По словам разработчиков препарата, он подавляет активность ферментов, необходимых для размножения вируса. Лекарство прошло первые клинические испытания в Японии и доказало свою безопасность. Второй этап испытаний фармацевты планируют начать в ноябре, когда начнется сезонный пик заболевания. Если испытания пройдут удачно, то препарат может поступить в продажу уже в начале 2018 года. Существующие лекарства от гриппа справляются с болезнью примерно за пять дней.
Japan stocks were lower after the close on Tuesday, as losses in the Pharmaceutical Industry, Transportation Equipment and Services sectors led shares lower. At the close in Tokyo, the Nikkei 225 lost 2.43% to hit a new 6-months low. The best performers of the session on the Nikkei 225 were Pioneer Corp. (TOKYO:6773), which rose 8.41% or 19.0 points to trade at 245.0 at the close. Meanwhile, Kobe Steel, Ltd. (TOKYO:5406) added 3.29% or 5.0 points to end at 157.0 and Tokuyama Corp. (TOKYO:4043) was up 3.11% or 6.0 points to 199.0 in late trade. The worst performers of the session were Shionogi&Co., Ltd. (TOKYO:4507), which fell 8.82% or 415.0 points to trade at 4290.0 at the close. Kikkoman Corp. (TOKYO:2801) declined 8.05% or 280.0 points to end at 3200.0 and Kajima Corp. (TOKYO:1812) was down 7.50% or 50.0 points to 617.0. Falling stocks outnumbered advancing ones on the Tokyo Stock Exchange by 1581 to 294 and 1 ended unchanged. The Nikkei Volatility, which measures the implied volatility of Nikkei 225 options, was up 1.96% to 35.94. Crude oil for October delivery was down 3.19% or 1.47 to $44.58 a barrel. Elsewhere in commodities trading, Brent oil for delivery in October rose 0.96% or 0.46 to hit $48.09 a barrel, while the December Gold contract fell 0.12% or 1.40 to trade at $1120.00 a troy ounce. USD/JPY was up 0.45% to 119.81, while EUR/JPY rose 0.71% to 134.18. The US Dollar Index was down 0.20% at 95.95.
Japan stocks were higher after the close on Tuesday, as gains in the Transport, Paper&Pulp and Fishery sectors led shares higher. At the close in Tokyo, the Nikkei 225 rose 0.12% to hit a new all time high. The best performers of the session on the Nikkei 225 were JFE Holdings, Inc. (TOKYO:5411), which rose 4.52% or 130.5 points to trade at 3015.5 at the close. Meanwhile, Fujitsu Ltd. (TOKYO:6702) added 3.93% or 26.5 points to end at 700.5 and Nippon Steel&Sumitomo Metal Corp. (TOKYO:5401) was up 3.51% or 11.4 points to 335.8 in late trade. The worst performers of the session were Shionogi&Co., Ltd. (TOKYO:4507), which fell 1.62% or 75.0 points to trade at 4565.0 at the close. Sony Financial Holdings Inc. (TOKYO:8729) declined 1.52% or 33.0 points to end at 2142.0 and Daiichi Sankyo Co., Ltd. (TOKYO:4568) was down 1.42% or 33.5 points to 2331.5. Falling stocks outnumbered advancing ones on the Tokyo Stock Exchange by 1063 to 820. Shares in Nippon Steel&Sumitomo Metal Corp. (TOKYO:5401) rose to 52-week highs; rising 3.51% or 11.4 to 335.8. The Nikkei Volatility, which measures the implied volatility of Nikkei 225 options, was down 0.74% to 17.37 a new 6-months low. Crude oil for July delivery was down 0.29% or 0.17 to $59.55 a barrel. Elsewhere in commodities trading, Brent oil for delivery in July fell 0.37% or 0.24 to hit $65.28 a barrel, while the August Gold contract fell 0.71% or 8.60 to trade at $1196.30 a troy ounce. USD/JPY was up 0.78% to 122.51, while EUR/JPY rose 0.06% to 133.52. The US Dollar Index was up 0.69% at 97.13.
Citing an insufficient Rapiacta royalty stream from partner Shionogi & Co. to pay accrued interest in arrears on the non-recourse PharRMA Notes by the September 1, 2014 payment date, a BioCryst Pharmaceuticals (BCRX -0.8%) subsidiary defaults on the debt.Note holders may pursue acceleration of the notes, foreclose on the debt collateral and equity interest of the company in its wholly-owned subsidiary JPR Royalty Sub LLC and exercise other remedies. If they choose to pursue these actions future royalties from Shionogi may be at risk.The company may also incur costs associated with retiring the notes and liquidating the related currency hedge agreement if the notes are retired.BioCryst does not expect the situation to have a significant effect on its operations or cash flows. Post your comment!
U.S. health regulators said on Tuesday they have approved a drug made by Japan's Shionogi & Co to treat women experiencing pain during sexual intercourse. The U.S. Food and Drug Administration approved the drug, Osphena, for a type of pain known as dyspareunia, which is a symptom of vulvar and…